Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses the results of a real-world analysis evaluating the clinical outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar